BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 24097303)

  • 21. Molecular subtypes of breast cancer: metabolic correlation with ¹⁸F-FDG PET/CT.
    García Vicente AM; Soriano Castrejón Á; León Martín A; Chacón López-Muñiz I; Muñoz Madero V; Muñoz Sánchez Mdel M; Palomar Muñoz A; Espinosa Aunión R; González Ageitos A
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1304-11. PubMed ID: 23632960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The correlation of
    Qu YH; Long N; Ran C; Sun J
    Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients.
    Straver ME; Aukema TS; Olmos RA; Rutgers EJ; Gilhuijs KG; Schot ME; Vogel WV; Peeters MJ
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1069-76. PubMed ID: 20130860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
    Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
    J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
    Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
    Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.
    Humbert O; Berriolo-Riedinger A; Cochet A; Gauthier M; Charon-Barra C; Guiu S; Desmoulins I; Toubeau M; Dygai-Cochet I; Coutant C; Fumoleau P; Brunotte F
    Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):416-27. PubMed ID: 24258007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours.
    Toba H; Kondo K; Sadohara Y; Otsuka H; Morimoto M; Kajiura K; Nakagawa Y; Yoshida M; Kawakami Y; Takizawa H; Kenzaki K; Sakiyama S; Bando Y; Tangoku A
    Eur J Cardiothorac Surg; 2013 Aug; 44(2):e105-12. PubMed ID: 23674658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of Clinical Molecular Typing of Breast Invasive Ductal Carcinoma Using
    Zhang J; Liu Y; Fan H; Wang W; Shao W; Cao G; Shi X
    Acad Radiol; 2023 Sep; 30 Suppl 2():S82-S92. PubMed ID: 36624021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
    Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
    Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy.
    Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):32-40. PubMed ID: 23929431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between semiquantitative PET parameters and molecular subtypes of breast invasive ductal carcinoma.
    Chiacchio S; Evangelista L; Alsharif A; Manca G; DI Martino F; Negri A; Tredici M; Cervino AR; Puccini G; Filidei E; Ghilli M; Naccarato AG; Roncella M; Volterrani D
    Q J Nucl Med Mol Imaging; 2018 Mar; 62(1):101-111. PubMed ID: 26329496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of breast imaging parameters obtained from
    Grapin M; Coutant C; Riedinger JM; Ladoire S; Brunotte F; Cochet A; Humbert O
    Eur J Radiol; 2019 Apr; 113():81-88. PubMed ID: 30927964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.
    Jung NY; Kim SH; Choi BB; Kim SH; Sung MS
    World J Surg Oncol; 2015 Mar; 13():113. PubMed ID: 25889560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of
    Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
    Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Additional value of
    van Ramshorst MS; Teixeira SC; Koolen BB; Pengel KE; Gilhuijs KG; Wesseling J; Rodenhuis S; Valdés Olmos RA; Rutgers EJ; Vogel WV; Sonke GS; Vrancken Peeters MT
    Cancer Imaging; 2017 May; 17(1):15. PubMed ID: 28545563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic activity of breast cancer metastatic lesions on positron emission tomography/computed tomography: comparison with histological and biological characteristics of primary tumor.
    Sobic Saranovic D; Stojiljkovic M; Susnjar S; Odalovic S; Artiko V; Pavlovic S; Grozdic-Milojevic I; Obradovic V
    Neoplasma; 2016; 63(2):313-21. PubMed ID: 26774154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer.
    Soussan M; Orlhac F; Boubaya M; Zelek L; Ziol M; Eder V; Buvat I
    PLoS One; 2014; 9(4):e94017. PubMed ID: 24722644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?
    Groheux D; Majdoub M; Tixier F; Le Rest CC; Martineau A; Merlet P; Espié M; de Roquancourt A; Hindié E; Hatt M; Visvikis D
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1682-1691. PubMed ID: 26140849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between 18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography and Clinicopathological Features in Invasive Ductal Carcinoma of the Breast.
    Ito M; Shien T; Kaji M; Mizoo T; Iwamoto T; Nogami T; Motoki T; Taira N; Doihara H; Miyoshi S
    Acta Med Okayama; 2015; 69(6):333-8. PubMed ID: 26690243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.